NCT04661644View on ClinicalTrials.gov

Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

April 22, 2024

Study Completion Date

July 1, 2024

Conditions
Critical Limb Ischemia
Interventions
BIOLOGICAL

Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)

Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)

BIOLOGICAL

Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)

Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

Dt&Sanomedics

INDUSTRY

lead

S.Biomedics Co., Ltd.

INDUSTRY

NCT04661644 - Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia | Biotech Hunter | Biotech Hunter